CME Presentations

Rare Cancers Congress


Presentations


Speakers

  • Catherine Broome, MD

    Catherine Broome, MD

    Catherine Broome, MD

    Associate Professor of Medicine

    Catherine M. Broome, MD, is associate professor of medicine at Georgetown University and medical director of cellular apheresis in the Lombardi Comprehensive Cancer Center at MedStar Georgetown University Hospital in Washington, DC. A fascination with the science of hematology and the opportunity to develop a strong relationship with patients and their families led her to specialize in hematology and medical oncology. Dr Broome has authored or co-authored several peer-reviewed scientific articles and has been invited to speak both nationally and internationally. She is a member of the American Society of Hematology. Dr Broome received her medical degree from Louisiana State University School of Medicine in Shreveport.
  • Steven Horwitz, MD

    Steven Horwitz, MD

    Steven Horwitz, MD

    Attending Physician

    Steven Horwitz, MD, is an attending physician in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City. Dr Horwitz’s current research is dedicated to investigating immunotherapeutic approaches to identify better treatments for individuals with T-cell lymphomas and understanding mechanisms of response and resistance to novel drugs in T-cell lymphoma. He participates in several national and international committees dedicated to the advancement of T-cell lymphoma treatment, including as the chair of the National Comprehensive Cancer Network panel on Guidelines for Treatment of T-Cell/Primary Cutaneous B-Cell Lymphomas since 2017. Dr Horwitz earned his medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio.
  • Ayalew Tefferi, MD

    Ayalew Tefferi, MD

    Ayalew Tefferi, MD

    Professor of Hematology and Internal Medicine

    Ayalew Tefferi, MD, is professor of hematology and internal medicine in the Division of Hematology at the Mayo Clinic College of Medicine in Rochester, Minnesota. His clinical and laboratory interests focus on myeloid malignancies, including myeloproliferative neoplasms (MPN), myelodysplastic syndromes, acute leukemia, and chronic myelomonocytic leukemia. Dr Tefferi is best known for his groundbreaking work in defining the pathogenesis and prognostic features of MPN. His academic and research achievements include over 1,000 publications. He is editor-in-chief of Blood Cancer Journal and a member of many societies, such as the American Society of Hematology (ASH), which honored him with the 2016 Henry M. Stratton Medal for Clinical/Translational Science.
  • Robert J. Kreitman, MD

    Robert J. Kreitman, MD

  • Jonathan Trent, MD, PhD

    Jonathan Trent, MD, PhD

    Jonathan Trent, MD, PhD

    Professor of Medicine

    Jonathan C. Trent, MD, PhD, is associate director for clinical research and the director of the Bone and Soft-tissue Sarcoma Group in the Sylvester Comprehensive Cancer Center at the University of Miami Hospital in Florida. His interests are in the clinical and translational research of sarcomas and direct care of sarcoma patients. The major focus of Dr Trent’s clinical, educational, and research efforts are with gastrointestinal stromal tumor (GIST), chondrosarcoma, and other sarcomas. His work involves the use of novel preoperative/postoperative clinical trials, cell lines, as well as collaborations with other disciplines. Dr Trent earned his MD and PhD in cancer biology from The University of Texas Health Science Center, where he also completed a residency in internal medicine.
  • Lori Wirth, MD

    Lori Wirth, MD

    Lori Wirth, MD

    Elizabeth and Michael Ruane Endowed Chair of Medical Oncology

    Lori J. Wirth, MD, is the Elizabeth and Michael Ruane Endowed Chair of Medical Oncology and medical director of Massachusetts General Hospital’s Center for Head and Neck Cancers, and associate professor of medicine at Harvard Medical School in Boston. She is an internationally recognized expert in advanced thyroid cancer and head and neck oncology, with expertise new therapies for head and neck and thyroid cancers. Dr Wirth is past chairperson of the International Thyroid Oncology Group, and sits on a number of national and international oncology committees, including the National Comprehensive Cancer Network’s Thyroid Committee. Dr Wirth received her medical director from Columbia University’s College of Physicians and Surgeons in New York City.
  • Jonathan R. Strosberg, MD

    Jonathan R. Strosberg, MD

    Jonathan R. Strosberg, MD

    Professor

    Jonathan Strosberg, MD, is a professor at Moffitt Cancer Center and leads Moffitt’s Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program in Tampa, Florida. He has published over 150 articles and book chapters on the diagnosis and management of neuroendocrine malignancies, including first-author publications in the New England Journal of Medicine and Journal of Clinical Oncology. Dr Strosberg is vice chair of the North American Neuroendocrine Tumor Society (NANETS), serves on the Neuroendocrine Guidelines Committee of the National Comprehensive Cancer Network (NCCN), on the Neuroendocrine Task Force of the National Cancer Institute (NCI), and co-chairs the Neuroendocrine Tumor Section of Southwest Oncology Group (SWOG).
  • Michael Heinrich, MD, FACP

    Michael Heinrich, MD, FACP

    Michael Heinrich, MD, FACP

    Professor of Cell, Developmental and Cancer Biology

    Michael Heinrich, MD, is a professor of medicine in cell, developmental, and cancer biology and in the Department of Medicine at Oregon Health Sciences University Knight Cancer Institute in Portland. His primary research interest is in the development of novel tyrosine kinase inhibitors for treatment of human cancers. Dr Heinrich's research includes both pre-clinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. A major focus of his research activities and clinical practice is the development of new treatments for patients with advanced gastrointestinal stromal tumors. Dr Heinrich earned his medical degree from the Johns Hopkins University School of Medicine in Baltimore, Maryland.
  • Ghassan Abou-Alfa, MD, MBA

    Ghassan Abou-Alfa, MD, MBA

    Ghassan Abou-Alfa, MD, MBA

    Professor

    Ghassan Abou-Alfa, MD, is an attending physician at Memorial Sloan Kettering Cancer Center and professor of medicine at Weill Medical School at Cornell University in New York City. He specializes in the treatment of gastrointestinal malignancies and his research focuses on incorporating small biological molecules and checkpoint inhibitors into standard cancer therapies. Dr Abou-Alfa is the immediate previous chair of the National Cancer Institute (NCI) Hepatobiliary Task Force, president for the International Society of Gastrointestinal Oncology (ISGIO), and a member of the NCI AIDS Malignancy Consortium Steering Committee. He strongly advocates for greater awareness of cancer’s global impact and continues to lead several international efforts with different institutions worldwide.

CME Information

Spotlight on Rare Cancers: Advancing Novel Therapy and Patient Centered Management


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Discuss coordination of care and clinical strategies to decrease the time to diagnosis for patients with rare cancers and blood disorders
  • Integrate patient-centered and evidence-based treatment options for rare cancers and blood disorders
  • Review emerging therapies under investigation as treatment options
  • Evaluate management strategies of adverse events to improve patient outcomes
  • Facilitate informed and shared decision-making through access to disease-related and support resources
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC (PQHE) working in collaboration with the National Organization for Rare Disorders (NORD).

ACKNOWLEDGEMENT

This activity is supported by educational grants from Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, LLC.; Eisai Inc.; Epizyme Inc.; Innate Pharma, Inc.; Ipsen Biopharmaceuticals, Inc.; Karyopharm Therapeutics; Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.; Sanofi Genzyme; and Seattle Genetics, Inc.

TUITION

Complimentary


JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM Logo

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, MOC credit is reported on a monthly basis.

To claim and receive MOC credits, learners must provide:
  • ABIM ID number
  • First and last name
  • Degree and specialty
  • DOB (MMDD)
  • Activity completion date

AAPA Credit Designation Statement

AAPA Logo

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 9.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 9.0 contact hour(s) (0.90 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2394-L01-P) – Track 1
Type of Activity: Application

(Universal Activity Number - JA4008162-9999-20-2395-L01-P) – Track 2
Type of Activity: Application

Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 9.0 contact hours.

ENDURING CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 9.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM Logo

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, MOC credit is reported on a monthly basis.

To claim and receive MOC credits, learners must provide:
  • ABIM ID number
  • First and last name
  • Degree and specialty
  • DOB (MMDD)
  • Activity completion date

AAPA Credit Designation Statement

AAPA Logo

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 9.0 AAPA Category 1 CME credits. Approval is valid until October 28, 2021. PAs should only claim credit commensurate with the extent of their participation.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 9.0 contact hour(s) (0.90 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-20-2396-H01-P)
Type of Activity: Application

Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 9.0 contact hours.

DATE OF RELEASE/EXPIRATION

Live Activity

Spotlight on Rare Cancers: Advancing Novel Therapy and Patient Centered Management

Wednesday, October 28, 2020 from 11:30am – 3:30pm ET: Track 1 - Rare Blood Disorders, Leukemias, and Lymphomas
  • 11:30am – 12:30pm ET: Cold Agglutinin Disease (CAD): The Role of the Complement Pathway in Treating a Rare Autoimmune Hemolytic Anemia
  • 12:30pm – 1:30pm ET: Addressing the Challenges of Peripheral T-Cell Lymphoma Management
  • 1:30pm – 2:30pm ET: Risk-Based Approach for Treatment of Myelofibrosis
  • 2:30pm – 3:30pm ET: Managing Relapsed/Refractory Hairy Cell Leukemia in the Community Setting
Thursday, November 12, 2020 from 9:00am – 2:00pm ET: Track 2 - Rare Solid Tumors
  • 9:00am – 11:00am ET: A Critical Update for the Multidisciplinary Team in Differentiating and Tailoring Management of Sarcomas
  • 11:00am – 11:30am ET: Where are we Headed in Thyroid Cancer? New and Emerging Treatment Approaches
  • 11:30am – 12:30pm ET: All About NETs: Disease Pathway, Treatment, and Clinical Trials for GEP-NETs, Pheochromocytoma, and Paragangliomas
  • 12:30pm – 1:30pm ET: Reducing Diagnostic Challenges and Expanding Treatment Options for Advanced GIST
  • 1:30pm – 2:00pm ET: Molecular Profiling and Targeted Therapies Shifting the Paradigm for Cholangiocarcinoma (Bile Duct Cancer)

Enduring Material

The enduring material will be available from October 28, 2020 to October 28, 2021

TARGET AUDIENCE

This activity is intended for community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, oncology nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists.

ESTIMATED TIME TO COMPLETE

Track 1 – 4 hours
Track 2 – 5 hours
Enduring activity – 9 hours

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test. For Pharmacists: Upon receipt of the completed activity evaluation form credit will be submitted to the NABP CPE Monitor Service. Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Catherine M. Broome, MD
Associate Professor of Medicine
MedStar Georgetown University
Lombardi Cancer Center
Consulting Fees: Alexion, Apellis, Argenx, Sanofi
Contracted Research: Alexion, Apellis, Argenx, Sanofi
Steven M. Horwitz, MD
Attending Physician
Memorial Sloan Kettering Cancer Center
Consulting Fees: ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, Trillium Therapeutics, Verastem, Vividion Therapeutics Contracted Research: ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium/Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem
Ayalew Tefferi, MD
Professor of Hematology and Internal Medicine
Division of Hematology
Mayo Clinic College of Medicine in Rochester, Minnesota
None
Robert J. Kreitman, MD
Hairy Cell Leukemia
Bethesda, Maryland
Royalty: Receive royalties from NIH as coinventor on NIH patent for Moxetumomab Pasudotox
Receipt of Intellectual Property Rights/Patent Holder: Coinventor on NIH patient for Moxetumomab Pasudotox
Jonathan C. Trent, MD, PhD
Professor of Medicine
Associate Director, Clinical Research
Director, Sarcoma Program
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Consulting Fee: Blueprint, C4 Therapeutics, Daiichi-Sankyo, Deciphera
Lori J. Wirth, MD
Elizabeth and Michael Ruane Endowed Chair of Medical Oncology
Associate Professor of Medicine, Harvard Medical School
Medical Director, Head and Neck Oncology
Massachusetts General Hospital
Consulting Fees: Bayer, Blueprint Medicines, Cue Biopharma, Eisai, Eli Lilly, Exelixis, Genentech, Loxo Oncology, Merck
Contracted Research: Ayala, Bayer, Eisai, Eli Lilly, Merck
Other DSMC: PDS Biotech
Jonathan R. Strosberg, MD
Professor
Moffitt Cancer Center
Consulting Fees: Novartis
Michael C. Heinrich, MD, FACP
Professor of Medicine
Professor of Cell, Developmental and Cancer Biology
OHSU Knight Cancer Institute
Royalty: Novartis
Consulting Fees: Blueprint Medicine, Deciphera Pharmaceuticals, Novartis
Fees for Non-CME/CE Services Received Directly from a Commercial Interest: Deciphera Pharmaceuticals
Ghassan Abou-Alfa, MD
Professor
Memorial Sloan Kettering Cancer Center
Consulting Fees (self): Agios, AstraZeneca, Autem, Bayer, Beigene, Berry Genomics, Debio, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Gilead, Helio, Incyte, Ipsen, Merck, MINA, QED, Redhill, Sillajen, Therabionics, Twoxar, Vector, Yiviva Consulting Fees (spouse): Celgene, CytomX, Loxo, Merck, Silenseed, Sobi, Twoxar Contracted Research (self): Agios, AstraZeneca, Bayer, Berry Genomics, BMS, Casi, Exelixis, Genoscience, Incyte, Polaris, Puma, QED, Sillajen Contracted Research (spouse): ActaBiologica, AstraZeneca, BMS, Celgene, Genentech/Roche, Halozyme, Mabvax, Silenseed

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.